2 Planned Clinical Trials to Test Ways of Preventing Alzheimer’s at Early Stages

2 Planned Clinical Trials to Test Ways of Preventing Alzheimer’s at Early Stages
Elenbecestat and BAN2401, two potential anti-amyloid therapies, were selected by the Alzheimer's Clinical Trials Consortium (ACTC) to be evaluated in clinical studies aiming to prevent progression to early stages of Alzheimer's disease. ACTC is a network of 35 primary clinical trial sites across the U.S., established by the National Institute on Aging (NIA) in 2017 is to accelerate and expand testing of possible Alzheimer’s treatments. Expected to start early next year, the so-called A3 and A45 studies will focus on the potential of elenbecestat and BAN2401 — being jointly developed by Eisai and Biogen — to slow disease progression in people at high risk of developing Alzheimer's or  showing very early signs of the disease. "The A3 and A45 Studies should provide critically important answers about the optimal time to intervene with anti-amyloid the
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *